Kuyesa Kwatsopano Kwachipatala kwa Advanced Solid Tumors ndi Hodgkin's Lymphoma

Glenmark Pharmaceuticals Limited inalandira chilolezo kuchokera kwa Indian drug regulator, Drug Controller General of India (DCGI), kuti achite kuyesa kwachipatala kwa Gawo 1 la buku lake laling'ono la molekyulu, GRC 54276, hematopoietic progenitor kinase 1 (HPK1) inhibitor. GRC 54276 ndi amodzi mwa mamolekyu ambiri ochokera ku Glenmark's, Innovative Medicines Group, motsogozedwa ndi Dr. Nikhil Amin, Chief Scientific Officer, omwe amagwira ntchito pakupanga magulu atsopano azinthu zofunikira zachipatala zomwe sizinakwaniritsidwe. HPK1 ndiwowongolera kwambiri wa T cell, B cell ndi dendritic cell-mediated immune reactions, zomwe zimapangitsa kuti chitetezo cha mthupi chitetezeke poyambitsa ndi kuyambitsa ma T cell. GRC 54276 yawonetsa kuthekera kwa kupha maselo a chotupa mu maphunziro a preclinical ngati wothandizira m'modzi komanso kuphatikiza ndi ma checkpoint inhibitors, ndikupangitsa kuti ikhale yofunika kwambiri mu immuno-oncology.

Kafukufukuyu adzawunika chitetezo ndi kulekerera kwa GRC 54276 ngati monotherapy, komanso kuphatikiza ndi zoletsa zowunikira odwala omwe ali ndi zotupa zolimba kwambiri komanso Hodgkin's lymphoma. Glenmark adzayambitsa mayeso a Zachipatala a Gawo 1 ku India pofika Juni 2022, ndipo akukonzekera kutumiza IND ku US ndi Clinical Trial Applications ku Europe kuti ayambitse pulogalamu yapadziko lonse yophunzirira zachipatala.

"Choyesayesa cha Glenmark chakhala chopereka njira zatsopano zamathandizo m'malo ake achirengedwe. Ndife okondwa kuti molekyulu yathu yoyamba yochokera kugulu lomwe langopangidwa kumene la 'Innovative Medicines Group' mkati mwa Glenmark lalandira chivomerezo kuchokera kwa oyang'anira mankhwala ku India kuti ayambitse kuyesa kwachipatala kwa Gawo 1. Izi zimathandizira kukulitsa luso la Glenmark la kafukufuku wazachipatala ndipo ndi sitepe loyandikira popereka njira zothetsera khansa, "atero Glenn Saldanha, Wapampando & Woyang'anira Woyang'anira, Glenmark Pharmaceuticals Limited.